FULL SUPPLEMENT: TAZAROTENE AND PSORIASIS: BIOLOGIC UNDERPINNINGS THAT IMPACT DISEASE CONTROL

January 2023 | Volume 22 | Issue 1 | 3446171 | Copyright © January 2023


Published online January 1, 2023

Abstract
Fixed-combination HP 0.01%/TAZ 0.045% lotion is a single treatment that packs a "one-two punch" in terms of clinical efficacy and economic benefit. Given the excellent safety profile, limited contraindications, superb efficacy, and long-term maintenance of effect, HP 0.01%/TAZ 0.045% lotion can fit into the therapeutic toolkit for any patient afflicted with psoriasis.
In this supplement:

Oldie But Goodie
Research over the past several years has elucidated the pathophysiology of psoriasis, yielding both new treatment options and enhanced knowledge of the mechanisms of action of existing treatments.

Read full article here.

A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations
Psoriasis is a complex inflammatory disease, which can be triggered by the interplay among keratinocytes, various immune cells, and even dermal vascular endothelial cells. Understanding of the key players and cytokine/chemokine messengers involved in the initiation and maintenance of psoriasis has significantly evolved and led to numerous systemic biologic therapies targeting those specific components. These therapies, despite their successes, do not ubiquitously affect all pathogenic cellular pathways. They also carry their risks and may be contraindicated in certain patient populations. Therefore, other therapeutics are still necessary.

Read full article here.